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ABC avidin-biotin-peroxidase complex 
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dNTP deoxy-ribonucleoside triphosphate 
EDTA ethylene diamine tetraacetic acid 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
IHC immunohistochemistry 
MPNST malignant peripheral nerve sheath tumors 
MRI resonance imaging 
mRNA messenger ribonucleic acid 
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NKT-cells natural killer T-cells 
NPC nasopharyngeal carcinoma 
NSN normal spinal nerves 
PFA paraformaldehyde 
Real time RT-PCR real time reverse transcription-polymerase chain reaction 
RNase ribonuclease 
RT room temperature 
SDF stromal cell-derived factor 
SPS spinal schwannomas 
TBS Tris-buffered saline 
VS vestibular schwannomas 
WHO World Health Organization 
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1 Introduction 
 Origination, epidemiology and prognosis of meningiomas 
Meningiomas are neoplasms derived from arachnoidal cells and they can be found anywhere 
in the dura mater. Meningiomas are considered to be the second most common intracranial 
tumors and account for 13%-26% of all primary brain tumors (Louis et al. 2000). Most (about 
90%) of the meningiomas are slow growing benign tumors, classified as World Health 
Organization (WHO) grade I (Louis et al. 2007). However, atypical meningiomas (WHO 
grade II), which are characterized by increased cellularity and increased mitotic activity, 
account for approximately 8% of this tumor type. Anaplastic variants (WHO grade III), which 
make up approximately 2%, show a more aggressive biological behaviour and are associated 
with a high risk of local recurrence and a poor clinical outcome (Louis et al. 2000; Whittle et 
al. 2004). Meningiomas may invade adjacent structures, including dura mater, muscle and 
bone, and are considered to be anaplastic when invasion of the brain parenchyma is also 
present (Whittle et al. 2004). Compression or obstruction of cortical veins, venous sinuses, or 
ventricles is another complication and edema is a common occurrence in meningiomas, and 
may be related to the headaches and convulsions often seen in these patients (Pistolesi et al. 
2002; Yoshioka et al. 1999; Lieu et al. 2000). Surgery is the mainstay of treatment, with the 
likelihood of recurrence inversely related to the extent of resection (Whittle et al. 2004; 
DeMonte. 1995). The Simpson scaling system describes the degree of surgical resection as 
ranging from grade 1 (complete tumor, dura mater, and bone removal) to grade 5 (tumor 
biopsy) (Simpson. 1957). The recurrence rate for meningiomas is on average 10% after a 
complete resection and up to 50% after a incomplete resection (partial resection or biopsy) 
(Simpson. 1957). In addition, recurrence rates are higher for the more aggressive histologic 
variants, with 5-year recurrence rates of 38% for atypical meningiomas and 78% for 
malignant meningiomas (DeMonte. 1995). When patients were grouped by histological type 
of tumors, those with benign meningiomas had an overall 5-year survival rate of 70%, 
whereas the overall 5-year survival rates in patients with atypical and anaplastic meningiomas 
were 75% and 55%, respectively (McCarthy et al. 1998). Furthermore, accepted alternative 
therapies for patients who have failed surgical intervention are currently limited to 
radiotherapy which has been shown to decrease of delay recurrence (Whittle et al. 2004; 
- 2 - 
Rogers et al. 2007). Currently, there are no pharmaceutical agents that are routinely used for 
adjuvant therapy. 
 
 Origination, epidemiology and prognosis of schwannomas 
Schwannomas, benign peripheral nerve sheath neoplasm, usually encapsulated, are composed 
entirely of cells with the immunophenotype and ultrastructural features of Schwann cells. 
Synonyms include neurilemmomas and neurinomas (Scheithauer et al. 1999). Schwannomas 
occur in individuals of all ages, but show a peak incidence between the third and sixth 
decades (Scheithauer et al. 1999). No sex predilection is evident, although females are twice 
as often affected by central nervous system (CNS) schwannomas, while radiation-induced 
examples most often occur in males (Salvati et al. 1992). The tumor cells always stay on the 
outside of the nerve, but the tumor itself may either push the nerve aside and/or up against 
bony structure (thereby possibly causing damage). Schwannomas are relatively slow growing 
and can be removed surgically, but always can recur. Schwannomas can be conveniently 
subdivided according to location into intracranial (vestibular schwannomas, VS), intraspinal 
(spinal schwannomas, SPS), peripheral and visceral tumors (Scheithauer et al. 1999).  
 
A vestibular schwannoma, often called an acoustic neuroma, is a benign primary intracranial 
tumor of the myelin-forming cells of the vestibulocochlear nerve (CN VIII). The term 
“vestibular schwannoma” is the correct one because the tumor involves the vestibular portion 
of the 8
th
 cranial nerve and arises from Schwann cells, which are responsible for the myelin 
sheath in the peripheral nervous system. The vestibular schwannoma is the most frequent 
neoplasm of the lateral skull base. It accounts for 8% of all intracranial tumors (Tos et al. 
1984). It may cause fatal situation by compressing vital brainstem structures. Clinically, it 
commonly appears as a sporadic tumor leading to either unilateral hearing loss, vertigo, or 
tinnitus. Depending on the patient’s age, associated symptoms, hearing function, tumor 
growth rate, and localization, several therapy options can be given to the patient, such as, 
monitoring of tumor growth by regular magnetic resonance imaging (MRI) scans, surgical 
removal of the lesion (Samii et al. 2001), or gamma knife therapy (Prasad et al. 2000).  
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Spinal schwannomas (SPS), account for about 25% of primary intradural spinal cord tumors 
in adults (Celli et al. 2005; Dorsi et al. 2004). Most are solitary schwannomas, which can 
occur throughout the spinal canal (Dorsi et al. 2004). In the literature, 70% to 80% of SPS are 
reported to be intradural in location, and those extending through the dural aperture as a 
dumbbell mass with both intradural and extradural components account for another 15% 
(Jinnai et al. 2005). Intramedullary schwannomas are extremely rare (Celli et al. 2005). The 
beginning symptoms are varied in accordance with the level of the tumor. The mild to severe 
back pain is most common symptoms. When the SPS grow large, they may compress the 
spinal cord completely and cause several obvious signs and symptoms. These signs and 
symptoms include, tingling sensation, weakness and fatigue, shooting pain, numbness of the 
back and spine, pain that diversifies towards the lower parts of the body, including legs. 
Surgery is supposed to be the best option for the treatment of SPS. The total resection of the 
lesion, which is the generally reachable goal of surgery, allows for good results in the cases in 
which the preoperative clinical findings are not particularly severe. The prognosis of SPS 
correlates to the size and type of the tumors. The outcome of this disease also depends on the 
preoperative neurological condition of patient (Jinnai et al. 2005). 
 
Malignant peripheral nerve sheath tumor is a rare variety of soft tissue sarcoma of 
ectomesenchymal origin (Angelov et al. 2000). WHO originated the term “malignant 
peripheral nerve sheath tumor” replacing previous heterogeneous and often confusing 
terminology, such as malignant schwannoma, malignant neurilemmoma, and 
neurofibrosarcoma, for tumors of neurogenic origin and similar biological behavior (Wanebo 
et al. 1993). Malignant peripheral nerve sheath tumors (MPNST) may arise spontaneously in 
adult patients, although 5% to 42% of MPNST have an association with multiple 
neurofibromatosis Type-I (Evans et al. 2002). Examples originating from schwannomas are 
extremely rare (Woodruff et al. 1994). MPNST are usually observed in the extremities and 
trunk, in the deep soft tissue close to the distribution of sciatic nerve, branchial plexus and 
sacral plexus. Extremely rare examples occur in the head and neck region. Clinically, they 
present as an enlarging mass, often associated with pain and nerve deficit. MPNST are locally 
invasive lesions, frequently leading to multiple recurrences and eventual metastasic spread 
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(Patil et al. 2007). MPNST can spread with direct extension, hematogenous extension and 
through perineural spread. Lymph node metastasis is uncommon (Patil et al. 2007). Radical 
surgical resection is the treatment of choice in MPNST though they are biologically 
aggressive in nature (Ferner et al. 2002). However multimodality therapy, including surgical 
resection and adjuvant radiotherapy, is available, the prognosis remains poor and survival is 
found to be influenced by tumor location and size. Sex and cellular differentiation emerged as 
the new adverse prognostic factors for survival of the patients (Kar et al. 2006). 
 
 Characteristics of chemokines and their receptors 
Chemokines are 8- to 12-kDa peptides that bind to specific G-protein-coupled, seven-span 
transmembrane receptors on the plasma membrane of target cells. Most chemokines bind to 
multiple receptors, and the same receptor may bind to more than one chemokine (Bajetto et al. 
2002; Teicher et al. 2010). Chemokines are classified into four major subfamilies on the basis 
of the motif of the first two cysteine residues: CC, CXC, C and CX3C subfamilies (Zlotnik et 
al. 2000). The CXC-chemokines activate the CXC receptors (CXCR)1–6, CC-chemokines 
bind to the CC receptors (CCR) 1–10, and CX3CL1 exerts its effects through the CX3CR1 
(Barbieri et al. 2010). Chemokines play an essential role in cellular migration and intracellular 
communication and were originally observed as inducible cytokines facilitating the 
recruitment of specific leukocyte subsets (Murphy. 2002). They are also involved in many 
other physiological and pathological processes, including neoplasia, in which they play an 
important role through multiple mechanisms. Chemokines affect tumor cell proliferation, 
regulate the angiogenic/angiostatic processes, control cell migration and metastasis, and 
regulate the recruitment of the immune cells into the tumor mass (Bajetto et al. 2002). 
Chemokine receptors can signal cell migration, altered cytokine production, cell proliferation, 
apoptosis or survival. Some chemokines are constitutively expressed (for example 
CXCL12/SDF-1; CX3CL1/fractalkine) while others are expressed only in responses to 
specific stimuli. 
 
 Characteristics of CX3CL1 and CX3CR1 
CX3CL1 is the unique member of the CX3C class of chemokines. CX3CL1, originally 
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termed Fractalkine or Neurotactin, was cloned from activated endothelial cells and neurons 
respectively (Bazan et al. 1997). In contrast to most other chemokines, CX3CL1 is expressed 
as a transmembrane molecule, composed of a chemokine head tethered to the cell membrane 
by a mucine-stalk, followed by a membrane-spanning domain and a short cytoplasmic tail 
(Bazan et al. 1997). Unlike other chemokines, it exists in two forms, each mediating distinct 
biological actions (Imai et al. 1997; Fong et al. 1998). The membrane-anchored protein, 
which is primarily expressed on the inflamed endothelium, serves as an adhesion protein 
promoting the retention of monocytes and T cells in inflamed tissue. The soluble form 
resembles more a conventional chemokine and strongly induces chemotaxis. Both chemotaxis 
and adhesion are mediated by the G protein-coupled receptor CX3CR1. Unlike many 
promiscuous chemokines, it only signals through the CX3CR1 receptor (Ransohoff. 2009). 
The receptor CX3CR1 is predominantly expressed by hematopoietic cells, natural killer (NK) 
cells, Th1 lymphocytes, CD14+ monocytes and by microglia in the spinal cord and satellite 
cells in the dorsal root ganglia (Hughes et al. 2002; Verge et al. 2004). As a result of both the 
adhesion and chemoattractant activities of the chemokine, CX3CL1 has been thought to play 
an important role in inflammation, and indeed, accumulating evidence indicates that 
CX3CL1/CX3CR1 are involved in the pathogenesis of various inflammatory disorders such 
as glomerulonephritis, rheumatoid arthritis and systemic lupus erythematosus (Yajima et al. 
2005; Ito et al. 2002; Sawai et al. 2005; Blaschke et al. 2003). CX3CL1 may be also involved 
in the pathogenesis of several diseases including atherosclerosis, cancer, and acquired 
immune deficiency syndrome (Braunersreuther et al. 2007; Zhang et al. 2007; Becker et al. 
2007). Based on the chemotactic and adhesive properties, the CX3CL1/CX3CR1 complex 
may mediate either pro- or anti-tumor effects as well (D’Haese et al. 2010). However, it is still 
not clear whether CX3CL1/CX3CR1 are involved in tumorigenesis of human meningiomas 
and schwannomas. 
 
 Characteristics of CXCL16 and CXCR6 
The CXC-chemokine CXCL16 is different from nearly all other known chemokines by its 
structure and function. CXCL16 is synthesized as transmembrane multi-domain molecule 
consisting of a chemokine domain followed by a glycosylated mucin-like stalk and a single 
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transmembrane helix. The only other transmembrane chemokine is CX3CL1/fractalkine as 
mentioned above. The chemokine CXCL16 was originally discovered as scavenger receptor 
for oxidized low-density lipoprotein (oxLDL) and therefore also termed SR-PSOX (Shimaoka 
et al. 2000) and independently as ligand for the CXC-chemokine receptor CXCR6 (also 
termed Bonzo, TYMSTR, STRL33). CXCL16 is the only ligand for the receptor CXCR6, and 
its soluble form induces the directional migration of CXCR6+ cells, such as CD4+ effector 
memory T cells and natural killer T-cells (NKT-cells) (Wilbanks et al. 2001; Matloubian et al. 
2000). In its stalk-bound form, CXCL16 has also been shown to facilitate the adhesion of 
CXCR6+ cells via interactions with the chemokine domain (Shimaoka et al. 2004) similar to 
the interaction between CX3CL1 and CX3CR1 (Ludwig et al. 2007). The expression of the 
chemokine CXCL16 has been reported previously for monocytes/macrophages, B cells, 
dendritic cells keratinocytes and endothelial cells (Hase et al. 2006; Ludwig et al. 2005; 
Shimaoka et al. 2000) while the receptor CXCR6 has been found on activated T cells, 
NKT-cells, bone marrow plasma cells and smooth muscle cells (Chandrasekar et al. 2004; 
Hase et al. 2006; Matloubian et al. 2000). Furthermore, CXCL16 expression was discovered 
also within the human brain on endothelial cells, activated astroglial cells and glioma cells 
(Ludwig et al. 2005). However, the expression of CXCL16/CXCR6 in human meningiomas is 
still unknown. 
 
 Characteristics of CXCL12 and CXCR4 
The stromal cell-derived factor (SDF)-1, recently renamed chemokine (CXC motif) ligand 12 
(CXCL12) is a member of the chemokine family, which consists of low-molecular-weight 
proteins (8-15 kD) produced by a variety of cells involved in the allergic inflammation 
(Shirozu et al. 1995). CXCL12/SDF-1 is a chemokine with two isoforms: SDF-1a, the 
predominant 89-amino acid protein form of SDF-1, and SDF-1b, which contains an extension 
of four amino acids at the carboxyl terminus. A third form of SDF (SDF-1g) was identified in 
rat that is identical to SDF-1b, except for the insertion of 30 additional amino acids at the 
carboxyl terminus (Gleichmann et al. 2000). CXCL12 is a homeostatic chemokine. The major 
function of homeostatic chemokines is to regulate hematopoietic-cell trafficking and 
secondary lymphoid-tissue architecture. CXCL12 also has different regulatory roles in several 
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biologic processes, including cardiac and neuronal development, stem cell motility, 
neovascularization, angiogenesis, apoptosis, and tumorigenesis (Atluri et al. 2008; Chen et al. 
2008; Hernández-López et al. 2008; Schönemeier et al. 2008; Zhang et al. 2008). The 
CXCL12 and its cognate receptor CXCR4 have recently taken on substantial interest because 
of their role in growth several human neoplasms (Balkwill. 2004). CXCL12/CXCR4 has been 
shown to be a key mediator of tumor spread, sitespecific metastasis, and patient survival 
(Burger et al. 2006). So, a study about the expression of CXCL12/CXCR4 in human 
schwannomas is required. 
 
1.4  Aims of the study 
Meningiomas and schwannomas are very common tumors in nervous system. Investigation in 
the molecular pathogenesis of meningiomas and schwannomas has the potential to improve 
diagnostic and therapeutic strategies, particularly for those with aggressive biological 
behaviour which always associated with a high risk of recurrence and a poor clinical outcome. 
As mentioned above, chemokines are involved in physiological and pathological processes of 
neoplasia. Chemokines and their receptors play a decisive role in tumor cell proliferation and 
survival. Little is known, however, about the role of chemokines in the pathogenesis of human 
meningiomas and schwannomas. So we decided to describe the expression of the 
CX3CL1/CX3CR1 and CXCL16/CXCR6 in human meningiomas, CX3CL1/CX3CR1 and 
CXCL12/CXCR4 in human schwannomas on mRNA and protein level, to figure the role of 
these chemokines and receptors in more detail. Elucidating the molecular mechanisms of 
these chemokine/receptor pairs in pathogenesis of human meningiomas and schwannomas we 
hope to get a deeper understanding of tumor development, and hope to identify possible 
targets for tumor therapy particularly for those with resistant to conventional therapy and poor 
prognosis. 
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2 Materials and Methods 
2.1  Clinical materials and tumor tissue procession 
Tumor tissue specimens used for our study were collected from 45 patients who were 
operated on between November 2000 and December 2010 at the Department of Neurosurgery, 
Kiel, Germany. The patients included 24 women and 21 men, aged 33 to 81 years at diagnosis, 
mean 58.6±9.4 years.  
 
2.2  RNA isolation 
Tissue samples including 10 for meningiomas WHO grade I, 10 for meningiomas WHO grade 
II, 7 for meningiomas WHO grade III, 6 for vestibular schwannomas (VS), 6 for spinal 
schwannomas (SPS), 6 for malignant peripheral nerve sheath tumors (MPNST), 5 for dura, 3 
for normal spinal nerves (NSN) and 2 for normal 8
th
 cranial nerves (NCN) were homogenized 
in 1 ml of TRIZOL
®
 Reagent per 50-100mg tissue by using a Polytron-homogenizer. After 
centrifugation at 12000 rpm for 10 minutes at 4℃，the cleared homogenate solution was 
transferred to a flesh tube. After addition of 0.2 ml of chloroform, the solution was shaken 
vigorously by hand for 15 seconds, and then incubated at 15  to 30  for 2℃ ℃ -3 minutes. After 
a centrifugation step at no more than 12000 rpm for 15 minutes at 4 , the mixtures were ℃
separated into a red low phenol-chloroform phase, an interphase and a colorless upper 
aqueous phase. The aqueous phase was transferred to a fresh tube and mixed with 0.5 ml 
isopropyl alcohol. After this, the solution was incubated at 25  for 10 minutes and ℃
centrifugation at no more than 12000 rpm for 10 minutes at 4 . By this, the RNA was ℃
precipitated from the aqueous phase and formed a gel-like white pellet on the bottom of tube. 
After removing the supernatant, the RNA pellet was washed with 1 ml 75% ethanol. After 
centrifugation at no more than 7500 rpm for 5 minutes at 4  and removing the supernatant, ℃
the RNA pellet was briefly dried (air-dry for 5-10 minutes) and dissolved in RNase-free water. 
Then, the RNA was incubated for 10 minutes at 58 , and chilled in an ice bath. Finally, RNA ℃
concentrations were quantified by a spectrophotometer (E=260 nm, A260/A280 ratio) 
 
2.3  cDNA synthesis 
To destroy the contaminating genomic DNA interfering with RT-PCR experiments, 2µg of 
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RNA were added to RNase-free water (diluted in RNase-free water to 7µl), 1µl RNase free 
DNase (1u/µl) and 1µl 10×reaction buffer for DNA denaturation for 15 minutes at 37 . 1µl ℃
EDTA (20mM) was added to the mixture and incubation at 65  for 10 minutes to stop ℃
function of RNase free DNase. For first strand synthesis, at first the mixture was added to 2µl 
random hexamer primer (100µg/µl), incubated at 70℃ for 5 minutes and chilled on ice. Then 
4µl 5×reaction buffer, 2µl 10mM 4 dNTP mix, 1µl deionized water and 1µl RevertAid
TM
 H 
Minus M-MuLV Reverse Transcriptase (200u/µl) was added to the mixture and all was 
incubated at 25  for 10 minutes and then at 42  ℃ ℃ for 60 minutes. The process was stopped 
by heating the solution at 70  for 10 minutes, and by quickly chilling it on ice.℃  
 
2.4  Real-time RT-PCR 
Real-time RT-PCR was performed in three replicates of each sample using a total reactive 
volume of 20µl, which contained 1µl of 20×Assays-on-Demand
TM
 Gene Expression Assay 
Mix, 10µl of 2×TaqMan Universal PCR Master Mix and 100ng or 10ng of cDNA template 
(diluted in 9µl RNase-free water). After 2 minutes at 50  for uracil℃ -N-glycosylase activation 
and 10 minutes at 95  for polymerase activation, 40 cycles of 15 seconds at 95  ℃ ℃
(denaturation) and 1 minutes at 60  (annealing and extension) were run. ℃
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in each sample was tested as intrinsic 
positive control. Each plate included at least three “No Template Controls”. The reaction was 
carried out with the MyiQ
TM
 Single Color Real-time PCR Detection System. Fluorescent data 
were converted into cycle threshold (CT) measurements. CT of each sample was averaged and 
then analyzed by a comparative CT method for relative quantification of different gene 
expression. ∆CT =[ CT (10ng)-3.3+ CT (100ng)]/2- CT (GAPDH). 
 
2.5  Immunohistochemistry 
Based on the results of real-time RT-PCR, 3 samples of every subtype (meningiomas grade I, 
II, III, dura, SPS, VS, NSN) and 2 samples of MPNST, NCN were investigated by 
immunohistochemistry (IHC). 
For IHC examination, fresh-frozen tumor tissues were cut in a freezing cryostat into 10µm 
slice sections. The sections were air dried and stored in -20  free℃ zer until used. 
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IHC was performed using the avidin-biotin-peroxidase complex (ABC) method. The 
serum-control and isotype-control were performed for every primary antibody. The slices 
were post-fixation with 4% Para-formaldehyde (PFA) (4 ) in ℃ Tris-buffered saline (TBS) for 
30 minutes at room temperature (RT). Then, the slices were rinsed in TBS 10 minutes for 2 
times. To block endogenous peroxidase and non-specific binding, 3% H2O2 in 0.3% Triton 
X-100/TBS was used for 30 minutes at RT. After incubation of the slices in TBS 10 minutes 
for 2 times, diluted normal blocking serum (appropriate 10%) in TBS for 60 minutes at RT 
was used, respectively. The slides were directly transferred to an appropriate dilution of 
primary antibodies (see table 1). The antibodies were diluted in 0.3% Triton X-100/TBS and 
2% normal blocking serum in TBS. Meanwhile, the isotype-control was directly transferred to 
an appropriate dilution of corresponding IgG without primary antibodies (see table 1), and the 
serum-control was directly transferred to the diluent of 2% normal serum and 0.3% Triton 
X-100/TBS. Then, sections were incubated at 4℃ over night. After washing steps with TBS 
(10 minutes for 2 times), the slides were incubated with corresponding biotinylated second 
antibody (dilution 1:200) in 1.5% blocking serum in TBS for 60 minutes at RT (see table 1). 
After washing the slices in TBS 10 minutes for 2 times, amplification of the signal was 
carried out by ABC method with ABC Vectastain
®
 kit. The signal was visualized by 
incubation with 0.06% 3,3’-diaminobenzidine-tetrahydrochloride (DAB) and 0.003% H2O2 in 
0.1M Tris-HCl (pH 7.6) for about 3 minutes. Then, the slides were counterstained with 
Mayer’s Hämalaun for 60 second. After washing with running tap water for 10 minutes, the 
slides were grads-dehydrated with ethanol (concentration from 70% → 80% → 95% → 95% 
→ 100% → 100%, 1 minutes for each concentration). After cleared in RotiClear 10 minutes 
for 3 times, the slides were mounted with RotiMount
®
 quick-harden mounting medium and 
coverslipped for investigation. Brightfield microscopy with digital photography was 
performed using a Zeiss microscope and Zeiss camera. 
The immunostaining was assessed quantitatively as the percentage of positive cells in relation 
to negative ones. To evaluate immunohistochemical expression of chemokines markers in 
samples, five random fields around the center of the tissue were used for cell counting in each 
slide at 200×magnification, and the percentages of immunoreactive cells per field were 
averaged. 
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Table 1  Antibodies used for detection of tumor cell markers 
 Antibody 
Original 
Concentration 
Diluent’s 
Concentration 
Source 
Primary 
Antibody 
CX3CL1 500µg/ml 1:200 Mouse Monoclonal 
CX3CR1 200µg/ml 1:200 Rabbit Polyclonal 
CXCL16 100µg/ml 1:200 Goat Polyclonal 
CXCR6 500µg/ml 1:50 Mouse Monoclonal 
CXCL12 200µg/ml 1:100 Rabbit Polyclonal 
CXCR4 1000µg/ml 1:300 Rabbit Polyclonal 
Isotype control for CX3CL1 500µg/ml 1:200 Normal Mouse IgG 
Isotype control for CX3CR1 1000µg/ml 1:1000 Normal Rabbit IgG 
Isotype control for CXCL16 1000µg/ml 1:2000 Normal Goat IgG 
Isotype control for CXCR6 500µg/ml 1:50 Normal Mouse IgG 
Isotype control for CXCL12 1000µg/ml 1:500 Normal Rabbit IgG 
Isotype control for CXCR4 1000µg/ml 1:300 Normal Rabbit IgG 
Secondary 
Antibody 
Biotimylated 
anti-Mouse 
1.5mg/ml 1:200 Horse 
Biotimylated 
anti-Rabbit 
1.7mg/ml 1:200 Donkey 
Biotimylated 
anti-Goat 
1.5mg/ml 1:200 Rabbit 
 
2.6  Statistical analysis 
Statistical analysis were investigated for the following factors: 1) Comparison about the ∆CT 
values of real-time RT-PCR between meningiomas of different WHO grades and dura; 2) 
Comparison about the ∆CT values of real-time RT-PCR between VS and NCN; 3) Comparison 
about the ∆CT values of real-time RT-PCR between MPNST, SPS and NSN; 4) Comparison 
about the percentages of immunostained cells between meningiomas of different WHO grades 
and dura; 5) Comparison about the percentages of immunostained cells between VS and NCN;  
6) Comparison about the percentages of immunostained cells between MPNST, SPS and NSN; 
7) Correlation between the mRNA expression (∆CT values of real-time RT-PCR)  of 
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chemokines and its receptors in meningiomas of different WHO grades; 8) Correlation 
between the mRNA expression (∆CT values of real-time RT-PCR) of chemokines and its 
receptors in schwannomas (including VS and SPS) and MPNST. The statistical analysis was 
carried out with SPSS 10.0 for windows (SPSS Inc, Chicago, IL, USA). Student’s t-test with 
independent samples and bivariate correlation analysis (Pearson correlation coefficients) were 
used. Significance level in all tests was P=0.05. 
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3  Results 
3.1  Patients’ materials 
A total amount of 45 fresh frozen tumor tissue specimens were analyzed in the study. The 
group included 24 women and 21 men, with a mean age of 58.6±9.4 years at diagnosis. 
Tumor tissue consisted of 10 meningiomas WHO grade I, 10 meningiomas WHO grade II, 7 
meningiomas WHO grade III, 6 spinal schwannomas (SPS), 6 vestibular schwannomas (VS) 
and 6 malignant peripheral nerve sheath tumors (MPNST). Only one tumor tissue specimen 
obtained from a recurrent meningioma WHO grade III, while the others were not from the 
recurrent tumors. First of all, we wanted to know whether chemokines and their receptors 
were expressed in these tumor tissues on mRNA level. By real-time RT-PCR, the mRNA 
levels of chemokines and their receptors were measured for all these samples. Of these 
materials, 3 samples of every subtype (meningiomas WHO grade I, II, III, SPS, VS) and 2 
samples of MPNST were investigated by IHC. The clinical data of patients are given in 
appendix 1. Meanwhile, 5 dura, 3 normal spinal nerves (NSN) and 2 normal 8
th
 cranial nerves 
(NCN) served as normal control samples, which were obtained from the Department of 
General Pathology, Kiel, Germany. 
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3.2  CX3CL1 expression in meningiomas 
First, we evaluate CX3CL1 expression in different meningiomas on mRNA level by real-time 
RT-PCR. In general, compared to the normal dura a down-regulated mRNA expression of 
CX3CL1 was found in meningiomas of all different WHO grades (see figure 1-I). Thereby, 
the mean normalized ∆CT values were 5.16 in meningiomas of all WHO grades and 2.52 in 
normal dura, which means that CX3CL1 mRNA expression in meningiomas decreased about 
6 folds over that in normal dura. However, CX3CL1 mRNA expression varied in different 
WHO grades of meningiomas. The average ∆CT values were 5.43, 4.84 and 5.23 in 
meningiomas grade I, II and III, respectively. Meanwhile, within the same subtype, CX3CL1 
mRNA expression also varied in different tissue samples (for instance, the ∆CT values differed 
from 0.76 to 4.86 in different dura samples). Compared to dura, a statistical significant 
difference of CX3CL1 mRNA expression could be found in meningiomas grade I (P<0.01), II 
(P<0.05) and III (P<0.01). 
 
Next, IHC was performed to evaluate CX3CL1 expression on the protein level in 
meningiomas of different WHO grades and normal dura. 3 samples of every subtype 
(meningiomas WHO grade I, II, III, dura) were chosen for IHC. Immunostaining of CX3CL1 
were found in all meningiomas and normal dura, and CX3CL1 positive cells were all stained 
brown compare to the serum-control and isotype-control (figure 1-II and 1-III). Overall, 
CX3CL1 positive cells varied in different WHO grades of meningiomas, the average 
percentages were 11.04%, 9.95% and 7.45% in meningiomas grade I, II and III, respectively 
(see figure 1-II). In contrast, 18.24% CX3CL1 positive cells were detected in normal dura 
(see figure 1-II). Meanwhile, within the same subtype, CX3CL1 positive cells also varied in 
different tissue samples. For example, the percentages of positive cells differed from 11.02% 
to 22.70% in different dura samples (see figure 1-II). Nevertheless, a statistical significant 
difference of the amounts of CX3CL1 positive cells was noted in meningiomas grade III 
compared to normal dura (P<0.05). There was a tendency that CX3CL1 was lower expressed 
in meningiomas grade I and II than in normal dura, though the difference was not significant.  
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Figure 1-I CX3CL1 mRNA expression 
in meningiomas and dura measured by 
real-time RT-PCR: Low ∆CT values 
indicate a high expression [logarithmic 
scale, a ∆CT = 3.3 corresponds to a 
10-fold difference, ∆CT = [CT(10ng) - 3.3 
+ CT(100ng)]/2 - CT(GAPDH)]. Individual 
points demonstrate normalized ∆CT 
values from individual samples. The 
mean normalized ∆CT values were 5.43, 
4.84 and 5.23 in meningiomas grade I, II 
and III, respectively and 2.52 in normal 
dura. Compared to dura, a statistical 
significant difference of CX3CL1 mRNA 
expression could be found in 
meningiomas grade I (P<0.01), II 
(P<0.05) and III (P<0.01).  
Figure 1-II Expression of CX3CL1 on 
the protein level in meningiomas of 
different WHO grades and dura: 
Individual points represent the 
percentages of CX3CL1 positive cells 
obtained by IHC. The average 
percentages of CX3CL1 positive cells 
were 11.04%, 9.95% and 7.45% in 
meningiomas grade I, II and III, 
respectively and 18.24% in normal dura. 
The lowest amounts of CX3CL1 positive 
cells were found in meningiomas grade 
III, and showed a statistical significant 
difference compared to normal dura 
(P<0.05).  
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Figure 1-III Immunohistochemical staining of CX3CL1 (original magnification ×200 of the first two lines, ×400 of the third line) in meningiomas of different 
WHO grades and dura. Immunostaining of CX3CL1 was found in all meningiomas and normal dura, and CX3CL1 positive cells were all stained brown compare to 
the serum-control and isotype-control (red arrow). The lowest amounts of CX3CL1 positive cells were found in meningiomas grade III, and the highest amounts 
were found in normal dura. (M1: Meningioma grade I; M2: Meningioma grade II; M3: Meningioma grade III) 
20µm                            20µm                           20µm                          20µm 
CX3CL1 Serum control Isotype control
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3.3  CX3CR1 expression in meningiomas 
In meningiomas of different WHO grades, CX3CR1 expression was observed by real-time 
RT-PCR and IHC as well (figure 2-I, II and III). 
CX3CR1 mRNA expression could be detected in all specimens of meningiomas and normal 
dura (see figure 2-I). The average ∆CT values were 5.71 in meningiomas of all WHO grades 
and 3.77 in normal dura. Meanwhile, CX3CR1 mRNA expression varied in different WHO 
grades of meningiomas. The mean normalized ∆CT values were 5.23, 4.54 and 8.06 in 
meningiomas grade I, II and III, respectively. Furthermore, within the same subtype, the 
normalized ∆CT values also varied in different tissue samples. For example, the normalized 
∆CT values differed from 4.53 to 11.22 in different meningiomas WHO grade III samples (see 
figure 2-I). Compared to dura, a statistical significant difference of CX3CR1 mRNA 
expression could be found only in meningiomas grade III (P<0.01). 
 
For IHC, immunostaining of CX3CR1 was found in all meningiomas and normal dura 
samples. Like CX3CL1, CX3CR1 positive cells were all stained brown compare to the 
serum-control and isotype-control (figure 2-II and III). The average percentages of CX3CR1 
positive cells were 11.37%, 14.04% and 7.52% in meningiomas grade I, II and III, 
respectively and 19.45% in normal dura (see figure 2-II). As same as real-time RT-PCR, a 
statistical significant difference of the amounts of CX3CR1 positive cells was noted only in 
meningiomas grade III compared to normal dura (P<0.05). The amounts of CX3CR1 positive 
cells were a little bit lower in meningiomas grade I and II than in normal dura, but the 
difference was not significant. 
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Figure 2-I CX3CR1 mRNA expression 
in meningiomas and dura measured by 
real-time RT-PCR: Low ∆CT values 
indicate a high expression [logarithmic 
scale, a ∆CT = 3.3 corresponds to a 
10-fold difference, ∆CT = [CT(10ng) - 3.3 
+ CT(100ng)]/2 - CT(GAPDH)]. Individual 
points demonstrate normalized ∆CT 
values from individual samples. The 
mean normalized ∆CT values were 5.23, 
4.54 and 8.06 in meningiomas grade I, II 
and III, respectively and 3.77 in normal 
dura. Compared to dura, a statistical 
significant difference of CX3CR1 
mRNA expression could be found in 
meningiomas grade III (P<0.01).  
Figure 2-II Expression of CX3CR1 on 
the protein level in meningiomas of 
different WHO grades and dura: 
Individual points represent the 
percentages of CX3CR1 positive cells 
obtained by IHC. The average 
percentages of CX3CR1 positive cells 
were 11.37%, 14.04% and 7.52% in 
meningiomas grade I, II and III, 
respectively and 19.45% in normal dura. 
The lowest amounts of CX3CR1 positive 
cells were found in meningiomas grade 
III, and showed a statistical significant 
difference compared to normal dura 
(P<0.05).  
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CX3CR1 expression in meningiomas 
 
Figure 2-III Immunohistochemical staining of CX3CR1 (original magnification ×200 of the first two lines, ×400 of the third line) in meningiomas of different 
WHO grades and dura. Immunostaining of CX3CR1 was found in all meningiomas and normal dura, and CX3CR1 positive cells were all stained brown compare to 
the serum-control and isotype-control (red arrow). The lowest amounts of CX3CR1 positive cells were found in meningiomas grade III, and the highest amounts 
were found in normal dura. (M1: Meningioma grade I; M2: Meningioma grade II; M3: Meningioma grade III) 
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3.4  CXCL16 expression in meningiomas 
Subsequently, CXCL16 mRNA expression in meningiomas of different WHO grades was 
confirmed by using real-time RT-PCR (figure 3-I). In general, compared to the normal dura a 
down-regulated mRNA expression of CXCL16 was found in meningiomas of all different 
WHO grades. The mean normalized ∆CT values were 4.28, 3.90 and 5.18 in meningiomas 
grade I, II and III, respectively and 2.84 in normal dura. Compared to dura, a statistical 
significant difference of CXCL16 mRNA expression could be found in meningiomas grade I 
(P<0.05) and III (P<0.01). Although CXCL16 was a little bit lower expressed in meningiomas 
grade II than in normal dura, the difference was not significant. 
 
Based on the results of real-time RT-PCR, the protein levels of CXCL16 were measured by 
IHC. Immunostaining of CXCL16 was found in all meningiomas and normal dura. 
Meanwhile, CXCL16 immunoreactive cells were all stained brown compare to the 
serum-control and isotype-control (figure 3-II and III). The average percentages of CXCL16 
immunoreactive cells were 16.19%, 18.13% and 11.78% in meningiomas grade I, II and III, 
respectively and 18.56% in normal dura (see figure 3-II). The amounts of CXCL16 positive 
cells in meningiomas grade III was lower than that in normal dura with a statistical significant 
difference (P<0.05). There was no statistical significant difference between meningiomas 
grade I and II compared to normal dura. 
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Figure 3-I CXCL16 mRNA expression 
in meningiomas and dura measured by 
real-time RT-PCR: Low ∆CT values 
indicate a high expression [logarithmic 
scale, a ∆CT = 3.3 corresponds to a 
10-fold difference, ∆CT = [CT(10ng) - 3.3 
+ CT(100ng)]/2 - CT(GAPDH)]. Individual 
points demonstrate normalized ∆CT 
values from individual samples. The 
mean normalized ∆CT values were 4.28, 
3.90 and 5.18 in meningiomas grade I, II 
and III, respectively and 2.84 in normal 
dura. Compared to dura, a statistical 
significant difference of CXCL16 mRNA 
expression could be found in 
meningiomas grade I (P<0.05) and III 
(P<0.01).  
Figure 3-II Expression of CXCL16 on 
the protein level in meningiomas of 
different WHO grades and dura: 
Individual points represent the 
percentages of CXCL16 positive cells 
obtained by IHC. The average 
percentages of CXCL16 positive cells 
were 16.19%, 18.13% and 11.78% in 
meningiomas grade I, II and III, 
respectively and 18.56% in normal dura. 
The lowest amounts of CXCL16 positive 
cells were found in meningiomas grade 
III, and showed a statistical significant 
difference compared to normal dura 
(P<0.05).  
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Figure 3-III Immunohistochemical staining of CXCL16 (original magnification ×200 of the first two lines, ×400 of the third line) in meningiomas of different 
WHO grades and dura. Immunostaining of CXCL16 were found in all meningiomas and normal dura, and CXCL16 positive cells were all stained brown compare to 
the serum-control and isotype-control (red arrow). The lowest amounts of CXCL16 positive cells were found in meningiomas grade III, and the highest amounts 
were found in normal dura. (M1: Meningioma grade I; M2: Meningioma grade II; M3: Meningioma grade III) 
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3.5  CXCR6 expression in meningiomas 
Then, we investigated CXCR6 mRNA expression in meningiomas of different WHO grades 
and normal dura by real-time RT-PCR as well (figure 4-I). In contrast to the normal dura, 
CXCR6 mRNA expression was relatively low in meningiomas. The mean normalized ∆CT 
values were 12.18, 10.91 and 12.15 in meningiomas grade I, II and III, respectively and 9.7 in 
normal dura. Based on high ∆CT values indicating low expression, the expression levels of 
CXCR6 were relatively lower in all grade of meningiomas and normal dura than that of other 
molecules investigated in this study. However, a statistical significant difference of CXCR6 
mRNA expression could be found in meningiomas grade I compared to normal dura (P<0.05).  
 
After that, CXCR6 protein expression was investigated by IHC. CXCR6 immunoreactive 
cells were found in all meningiomas and normal dura which were stained brown compare to 
the serum-control and isotype-control (figure 4-II and III). In meningiomas grade I, II and III, 
the mean percentages of CXCR6 positive cells were 5.84%, 6.73% and 6.75%, respectively. 
Normal dura expressed 8.75% CXCR6 positive cells (figure 4-II). No statistical significant 
differences could be found between meningiomas of different WHO grades and normal dura. 
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Figure 4-I CXCR6 mRNA expression in 
meningiomas and dura measured by 
real-time RT-PCR: Low ∆CT values 
indicate a high expression [logarithmic 
scale, a ∆CT = 3.3 corresponds to a 
10-fold difference, ∆CT = [CT(10ng) - 3.3 
+ CT(100ng)]/2 - CT(GAPDH)]. Individual 
points demonstrate normalized ∆CT 
values from individual samples. The 
mean normalized ∆CT values were 
12.18, 10.91 and 12.15 in meningiomas 
grade I, II and III, respectively and 9.7 in 
normal dura. Compared to dura, a 
statistical significant difference of 
CXCR6 mRNA expression could be 
found only in meningiomas grade I 
(P<0.05).  
Figure 4-II Expression of CXCR6 on 
the protein level in meningiomas of 
different WHO grades and dura: 
Individual points represent the 
percentages of CXCR6 positive cells 
obtained by IHC. The average 
percentages of CXCR6 positive cells 
were 5.84%, 6.73% and 6.75% in 
meningiomas grade I, II and III, 
respectively and 8.75% in normal dura. 
The amounts of CXCR6 positive cells 
were similar in all meningiomas and 
normal dura. No statistical significant 
differences could be found between 
meningiomas of different WHO grades 
and normal dura.  
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Figure 4-III Immunohistochemical staining of CXCR6 (original magnification ×200 of the first two lines, ×400 of the third line) in meningiomas of different WHO 
grades and dura. Immunostaining of CXCR6 was found in all meningiomas and normal dura, and CXCR6 positive cells were all stained brown compare to the 
serum-control and isotype-control (red arrow). The amounts of CXCR6 positive cells were similar in meningiomas of all WHO grades and normal dura. (M1: 
Meningioma grade I; M2: Meningioma grade II; M3: Meningioma grade III) 
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3.6  CX3CL1 expression in schwannomas 
To assess the potential role of CX3CL1 in different schwannomas, the expression of this 
chemokine on mRNA and protein level was examined by real-time RT-PCR and IHC. 
In general, CX3CL1 mRNA expression could be detected in all specimens of schwannomas 
and normal nerves. Compared to NCN and NSN, a down-regulated mRNA expression of 
CX3CL1 was found in VS, SPS and MPNST (see figure 5-I). Thereby, the mean normalized 
∆CT values were 7.15, 6.15 and 3.60 in VS, SPS and MPNST, respectively. Intriguingly, a 
significant difference of CX3CL1 mRNA expression could be detected between NCN and 
NSN. The mean normalized ∆CT values were 4.16 in NCN and -0.26 in NSN. Compared to 
NCN, a statistical significant difference of CX3CL1 mRNA expression could be found in VS 
(P<0.05). Compared to NSN, a statistical significant difference also could be found in SPS 
(P<0.01). 
 
For IHC, immunostaining of CX3CL1 was found in all schwannomas, malignant peripheral 
nerve sheath tumors and normal nerves. CX3CL1 positive cells were all stained brown 
compare to the serum-control and isotype-control (figure 5-II and 5-III). The average 
percentages of CX3CL1 positive cells were 5.78%, 6.86% and 11.07% in VS, SPS and 
MPNST, respectively (see figure 5-II). Like real-time RT-PCR, a difference of CX3CL1 
protein expression also could be found between NCN and NSN. The average percentages of 
CX3CL1 positive cells were 10.85% in NCN and 15.65% in NSN. Compared to NCN, no 
statistical significant difference of the amounts of CX3CL1 positive cells could be found in 
VS. Compared to NSN, a statistical significant difference could be found only in SPS 
(P<0.05), but there was no statistical significant difference between MPNST and NSN.  
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Figure 5-I CX3CL1 mRNA expression 
in schwannomas and normal nerves 
measured by real-time RT-PCR: Low  
∆CT values indicate a high expression 
[logarithmic scale, a ∆CT = 3.3 
corresponds to a 10-fold difference,   
∆CT = [ CT(10ng) - 3.3 + CT(100ng) ] / 2 - 
CT(GAPDH) ]. Individual points 
demonstrate normalized ∆CT values 
from individual samples. The mean 
normalized ∆CT values were 6.15, 3.60, 
7.15, -0.26 and 4.16 in SPS, MPNST, 
VS, NSN and NCN, respectively. 
Compared to NSN, a statistical 
significant difference of CX3CL1 mRNA 
expression could be found in SPS 
(P<0.01), and compared to NCN, a 
statistical significant difference could be 
found in VS (P<0.05).  
Figure 5-II  Expression of CX3CL1 on 
the protein level in schwannomas and 
normal nerves: Individual points 
represent the percentages of CX3CL1 
positive cells obtained by IHC. The 
average percentages of CX3CL1 positive 
cells were 6.86%, 11.07%, 5.78%, 
15.65% and 10.85% in SPS, MPNST, 
VS, NSN and NCN, respectively. Lower 
amounts of CX3CL1 positive cells were 
found in SPS and showed a statistical 
significant difference compared to NSN 
(P<0.05).  
(SPS: spinal schwannomas; MPNST: malignant peripheral nerve sheath tumors; VS: vestibular 
schwannomas; NCN: normal cranial nerves; NSN: normal spinal nerves) 
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Figure 5-III Immunohistochemical staining of CX3CL1 (original magnification ×200 of the first two lines, ×400 of the third line) in schwannomas and normal 
nerves. Immunostaining of CX3CL1 was found in MPNST, SPS, VS, NSN and NCN. CX3CL1 positive cells were all stained brown compare to the serum-control 
and isotype-control (red arrow). Low amounts of CX3CL1 positive cells were found in MPNST and SPS compared to NSN. Meanwhile low amounts of CX3CL1 
positive cells were also found in VS compared to NCN. (MPNST: malignant peripheral nerve sheath tumors; SPS: spinal schwannomas; VS: vestibular 
schwannomas; NSN: normal spinal nerves; NCN: normal cranial nerves) 
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3.7  CX3CR1 expression in schwannomas 
The mRNA levels of CX3CR1 were measured by real-time RT-PCR and determined in 
relation to that of GAPDH. CX3CR1 mRNA expression could be measured in all cases of the 
investigated samples except for one case in MPNST and another in NSN. Compared to NCN, 
remarkably up-regulated mRNA expression of CX3CR1 mRNA was found in VS. The mean 
normalized ∆CT values were 1.56 in VS and 5.01 in NCN with a statistical significant 
difference (P<0.01). However, the mean normalized ∆CT values were 1.04, 5.59 and 2.49 in 
SPS, MPNST and NSN, respectively. So, a slightly up-regulated expression of CX3CR1 
mRNA could be detected in SPS compared to NSN. In contrast to this, a down-regulated 
expression of CX3CR1 mRNA could be detected in MPNST compared to NSN. No statistical 
significant differences could be found between SPS, MPNST and NSN (see figure 6-I). 
 
Based on the results of real-time RT-PCR, protein level of CX3CR1 was detected by IHC. 
CX3CR1 positive cells were all stained brown compare to the serum-control and 
isotype-control (figure 6-II and 6-III). In VS and NCN, the mean percentages of CX3CR1 
positive cells were 18.95% and 10.32%, respectively (see figure 6-II). As same as real-time 
RT-PCR, the amounts of CX3CR1 positive cells in VS were higher than that in NCN with a 
statistical significant difference (P<0.05). In SPS, MPNST and NSN, the mean percentages of 
CX3CR1 positive cells were 15.69%, 11.10% and 12.71%, respectively. The amounts of 
CX3CR1 positive cells in SPS were also higher than that in NSN with a statistical significant 
difference (P<0.05). No statistical significant difference could be found between MPNST and 
NSN. 
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Figure 6-II Expression of CX3CR1 on 
the protein level in schwannomas and 
normal nerves: Individual points 
represent the percentages of CX3CR1 
positive cells obtained by IHC. The 
average percentages of CX3CR1 positive 
cells were 15.69%, 11.10%, 18.95%, 
12.71% and 10.32% in SPS, MPNST, 
VS, NSN and NCN, respectively. Low 
amounts of CX3CR1 positive cells were 
found in SPS, and showed a statistical 
significant difference with NSN 
(P<0.05). Compared to NCN, high 
amounts of CX3CR1 positive cells were 
found in VS (P<0.05). 
Figure 6-I CX3CR1 mRNA expression 
in schwannomas and normal nerves 
measured by real-time RT-PCR: Low  
∆CT values indicate a high expression 
[logarithmic scale, a ∆CT = 3.3 
corresponds to a 10-fold difference,   
∆CT = [ CT(10ng) - 3.3 + CT(100ng) ] / 2 - 
CT(GAPDH) ]. Individual points 
demonstrate normalized ∆CT values 
from individual samples. CX3CR1 
mRNA expression was undetectable in 
one MPNST sample and another NSN 
sample. The mean normalized ∆CT 
values were 1.04, 5.59, 1.56, 2.49 and 
5.01 in SPS, MPNST, VS, NSN and 
NCN, respectively. Compared to NCN, a 
statistical significant difference of 
CX3CR1 mRNA expression could be 
found in VS (P<0.05). No statistical 
significant differences could be found 
between SPS, MPNST and NSN. 
(SPS: spinal schwannomas; MPNST: malignant peripheral nerve sheath tumors; VS: vestibular 
schwannomas; NCN: normal cranial nerves; NSN: normal spinal nerves) 
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Figure 6-III  Immunohistochemical staining of CX3CR1 (original magnification ×200 of the first two lines, ×400 of the third line) in schwannomas and normal 
nerves. Immunostaining of CX3CR1 was found in MPNST, SPS, VS and normal nerves (NSN and NCN), and CX3CR1 positive cells were all stained brown 
compare to the serum-control and isotype-control (red arrow). Low amounts of CX3CR1 positive cells were found in MPNST compared to NSN and high amounts 
were found in SPS compared to NSN. Meanwhile, high amounts of CX3CR1 positive cells were found in VS compared to NCN. (MPNST: malignant peripheral 
nerve sheath tumors; SPS: spinal schwannomas; VS: vestibular schwannomas; NSN: normal spinal nerves; NCN: normal cranial nerves) 
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3.8  CXCL12 expression in schwannomas 
Then, we measured CXCL12 mRNA expression in VS, SPS and MPNST by real-time 
RT-PCR (see figure 7-I). CXCL12 mRNA expression could be detected in all schwannomas, 
MPNST and normal nerves. We found that the expression level of CXCL12 mRNA in NSN 
was remarkably higher than that in NCN. The mean normalized ∆CT values were 3.96 in NCN 
and -3.99 in NSN. Because of low ∆CT values indicating high expression, the expression 
levels of CXCL12 were relatively higher in schwannoms and MPNST than that of other 
molecules measured in this study. Thereby, the mean normalized ∆CT values were 1.93, 1.16 
and -2.21 in VS, SPS and MPNST, respectively. A up-regulated mRNA expression of 
CXCL12 was found in VS compared to NCN, but the difference was not significant. A 
down-regulated mRNA expression of CXCL12 was found in SPS and MPNST compared to 
NSN. A statistical significant difference of CXCL12 mRNA expression could be found only 
in SPS (P<0.01), but there was no statistical significant difference in MPNST compared to 
NSN. 
 
After that, CXCL12 protein expression in different schwannomas was confirmed by using 
IHC. CXCL12 positive cells were all stained brown compare to the serum-control and 
isotype-control (figure 7-II and 7-III). The average percentages of CXCL12 positive cells 
were 14.69%, 15.17% and 21.12% in VS, SPS and MPNST, respectively. A difference of 
CXCL12 protein expression also could be found between NCN and NSN. The average 
percentage of CXCL12 positive cells were 8.64% in NCN and 21.97% in NSN. No statistical 
significant difference of the amounts of CXCL12 positive cells could be found in VS 
compared to NCN. Compared to NSN, a statistical significant difference could be found only 
in SPS (P<0.05). No statistical significant difference could be found between MPNST and 
NSN.  
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CXCL12 expression in schwannomas
I) Real-time RT-PCR 
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Figure 7-II Expression of CXCL12 on 
the protein level in schwannomas and 
normal nerves: Individual points 
represent the percentages of CXCL12 
positive cells obtained by IHC. The 
average percentages of CXCL12 positive 
cells were 15.17%, 21.12%, 14.69%, 
21.97% and 8.64% in SPS, MPNST, VS, 
NSN and NCN, respectively. Low 
amounts of CXCL12 positive cells were 
found in SPS, and showed a statistical 
significant difference compared to NSN 
(P<0.05).  
Figure 7-I CXCL12 mRNA expression 
in schwannomas and normal nerves 
measured by real-time RT-PCR: Low  
∆CT values indicate a high expression 
[logarithmic scale, a ∆CT = 3.3 
corresponds to a 10-fold difference,   
∆CT = [ CT(10ng) - 3.3 + CT(100ng) ] / 2 - 
CT(GAPDH) ]. Individual points 
demonstrate normalized ∆CT values 
from individual samples. The mean 
normalized ∆CT values were 1.16, -2.21, 
1.93, -3.99 and 3.96 in SPS, MPNST, 
VS, NSN and NCN respectively. 
Compared to NSN, a statistical 
significant difference of CXCL12 mRNA 
expression could be found in SPS 
(P<0.01).  
(SPS: spinal schwannomas; MPNST: malignant peripheral nerve sheath tumors; VS: vestibular 
schwannomas; NCN: normal cranial nerves; NSN: normal spinal nerves) 
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CXCL12 expression in schwannomas 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-III Immunohistochemical staining of CXCL12 (original magnification ×200 of the first two lines, ×400 of the third line) in schwannomas and normal 
nerves. Immunostaining of CXCL12 was found in MPNST, SPS, VS and normal nerves (NSN and NCN), and CXCL12 positive cells were all stained brown 
compare to the serum-control and isotype-control (red arrow). Low amounts of CXCL12 positive cells were found in SPS compared to NSN and the amounts of 
CXCL12 positive cells were similar between MPNST and NSN. Meanwhile, high amounts of CXCL12 positive cells were found in VS compared to NCN. (MPNST: 
malignant peripheral nerve sheath tumors; SPS: spinal schwannomas; VS: vestibular schwannomas; NSN: normal spinal nerves; NCN: normal cranial nerves) 
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3.9  CXCR4 expression in schwannomas 
CXCR4 mRNA expression in different schwannomas was analyzed using real-time RT-PCR. 
And as same as CX3CR1, CXCR4 mRNA expression could be measured in all cases of the 
investigated samples except for one case in MPNST and another in NSN (figure 8-I). The 
mean normalized ∆CT values were 5.29 in VS and 6.84 in NCN. The CXCR4 mRNA 
expression in VS was slightly up-regulated, but no statistical significant difference could be 
obtained compared to NCN. However, the mean normalized ∆CT values were 4.74, 5.48 and 
4.01 in SPS, MPNST and NSN, respectively. A slightly down-regulated expression of CXCR4 
mRNA could be detected in SPS and MPNST compared to NSN. No statistical significant 
differences could be found between SPS, MPNST and NSN. 
 
Finally, CXCR4 protein expression in VS, SPS and MPNST were investigated by IHC. As 
same as CXCL12, CXCR4 positive cells were all stained brown compare to the serum-control 
and isotype-control (figure 8-II and 8-III). In VS and NCN, the mean percentages of CXCR4 
positive cells were 11.21% and 4.94%, respectively. The amounts of CXCR4 positive cells in 
VS were higher than that in NCN with a statistical significant difference (P<0.05). In SPS, 
MPNST and NSN, the mean percentages of CXCR4 positive cells were 11.54%, 10.59% and 
10.08%, respectively. There were no statistical significant differences between SPS, MPNST 
and NSN. 
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CXCR4 expression in schwannomas
I) Real-time RT-PCR 
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Figure 8-II Expression of CXCR4 on 
the protein level in schwannomas and 
normal nerves: Individual points 
represent the percentages of CXCR4 
positive cells obtained by IHC. The 
average percentages of CXCR4 positive 
cells were 11.54%, 10.59%, 11.21%, 
10.08% and 4.94% in SPS, MPNST, VS, 
NSN and NCN, respectively. High 
amounts of CXCR4 positive cells were 
found in VS, and showed a statistical 
significant difference compared to NCN 
(P<0.05). The amounts of CXCR4 
positive cells were similar between SPS, 
MPNST and NSN, and showed no 
statistical significant difference. 
Figure 8-I CXCR4 mRNA expression in 
schwannomas and normal nerves 
measured by real-time RT-PCR: Low 
∆CT values indicate a high expression 
[logarithmic scale, a ∆CT = 3.3 
corresponds to a 10-fold difference,   
∆CT = [ CT(10ng) - 3.3 + CT(100ng) ] / 2 - 
CT(GAPDH) ]. Individual points 
demonstrate normalized ∆CT values 
from individual samples. CXCR4 mRNA 
expression was undetectable in one 
MPNST sample and another NSN 
sample. The mean normalized ∆CT 
values were 4.74, 5.48, 5.29, 4.01 and 
6.84 in SPS, MPNST, VS, NSN and 
NCN, respectively. No statistical 
significant differences of CXCR4 mRNA 
expression could be found between SPS, 
MPNST and NSN. Meanwhile, no 
statistical significant difference could be 
found in VS compared to NCN. 
(SPS: spinal schwannomas; MPNST: malignant peripheral nerve sheath tumors; VS: vestibular 
schwannomas; NCN: normal cranial nerves; NSN: normal spinal nerves) 
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CXCR4 expression in schwannomas 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8-III Immunohistochemical staining of CXCR4 (original magnification ×200 of the first two lines, ×400 of the third line) in schwannomas and normal 
nerves. Immunostaining of CXCR4 was found in MPNST, SPS, VS and normal nerves (NSN and NCN), and CXCR4 positive cells were all stained brown compare 
to the serum-control and isotype-control (red arrow). The amounts of CXCR4 positive cells were found to be similar between SPS, MPNST and NSN. Meanwhile, 
high amounts of CXCR4 positive cells were found in VS compared to NCN. (MPNST: malignant peripheral nerve sheath tumors; SPS: spinal schwannomas; VS: 
vestibular schwannomas; NSN: normal spinal nerves; NCN: normal cranial nerves) 
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3.10  Correlations between chemokines (CX3CL1, CXCL16) and their receptors 
(CX3CR1, CXCR6) mRNA levels in meningiomas 
The chemokines and their respective receptors are co-expressed and associated among them at 
the mRNA level. So, in order to analyze the possible correlation between the expression levels 
of chemokines (CX3CL1,CXCL16) and their receptors (CX3CR1,CXCR6) in meningiomas, 
Pearson correlation analysis was used with SPSS 10.0 for windows (see figure 9-I and II). In 
all meningiomas samples, a positive correlation between the expression of CXCL16 and 
CXCR6 could be observed (P<0.01). On the contrary, no correlation between CX3CL1 and 
CX3CR1 expression could be found. Subsequently, the possible correlations were analyzed in 
different WHO grade memingiomas respectively. A positive correlation between the 
expression of CX3CL1 and CX3CR1 could be observed in WHO grade I (P<0.05), 
meanwhile a positive correlation between the expression of CXCL16 and CXCR6 could be 
observed in WHO grade II (P<0.01) and grade III (P<0.05).  
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Correlations between chemokines and their receptors in meningiomas 
 
Figure 9-I Correlation graphs between CX3CL1 and CX3CR1 mRNA expression: Each data point 
represents the value for an individual tumor. A significant positive correlation was observed in 
meningiomas grade I by the Pearson correlation analysis (P<0.05).  
 
 
Figure 9-II Correlation graphs between CXCL16 and CXCR6 mRNA expression: Each data point 
represents the value for an individual tumor. By the Pearson correlation analysis, significant positive 
correlation was observed in all meningiomas samples (P<0.01) and meningiomas grade II (P<0.01), grade 
III (P<0.05), respectively. 
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3.11  Correlations between chemokines (CX3CL1, CXCL12) and their receptors 
(CX3CR1, CXCR4) mRNA levels in schwannomas 
As same as meningiomas, Pearson correlation analysis was used to analyze the possible 
correlation between the expression levels of chemokines (CX3CL1, CXCL12) and their 
receptors (CX3CR1, CXCR4) in schwannomas (including SPS and VS) and MPNST (see 
figure 10-I and II). In all schwannomas samples, a positive correlation between the expression 
of CXCL12 and CXCR4 could be observed (P<0.05). On the contrary, no correlation between 
CX3CL1 and CX3CR1 expression could be found. In MPNST, no positive correlation could 
be observed between the expression of chemokines (CX3CL1, CXCL12) and their receptors 
(CX3CR1, CXCR4). 
 
Correlations between chemokines and their receptors in schwannomas 
 
Figure 10-I Correlation graphs between CX3CL1 and CX3CR1 mRNA expression: Each data point 
represents the value for an individual tumor. No significant positive correlation was observed in 
schwannomas and MPNST by the Pearson correlation analysis.  
 
 
Figure 10-II Correlation graphs between CXCL12 and CXCR4 mRNA expression: Each data point 
represents the value for an individual tumor. By the Pearson correlation analysis, a significant positive 
correlation was observed in schwannomas (P<0.05). 
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4  Discussion 
Most meningiomas and schwannomas are slowly growing benign tumors, however, many of 
them, as well as anaplastic meningiomas and malignant peripheral nerve sheath tumors 
(MPNST), show an aggressive biological and clinical behavior associated with high rates of 
recurrence and unfavorable prognosis. The molecular mechanisms involved in initiation, 
proliferation and progression of meningiomas and schwannomas are not yet fully understood.  
Chemokines are the largest family of cytokines in human immunophysiology. They are a 
family of peptide mediators that play an essential role in cell activation, differentiation, and 
trafficking. In addition to chemoattraction, recent investigations have suggested a possible 
role of chemokines in tumor growth and metastasis and in host-tumor response (Homey et al. 
2002). Additionally, several ligands activate the angiogenic switch in neoplastic tissues 
(Strieter et al. 2006; Müller et al. 2001; Balkwill et al. 2004; Menten et al. 2002). However, 
gene modification of chemokines was reported to play an important role in the induction of 
antitumor immunity in some animal neoplasms (Luster et al. 1993; Sgadari et al. 1997).  
In the brain, chemokines are expressed by astroglial, microglial, neuronal, meningeal and 
endothelial cells, and they may form – alongside with neurotransmitters and neuropeptides– a 
third major messenger system (Ambrosini et al. 2004; de Haas et al. 2007). Functionally, 
chemokines are linked in the physiological context with neuronal patterning (Reiss et al. 
2002), neuron–glia and glia–glia interactions as well as under pathological conditions with 
infections, chronic inflammatory diseases (e.g. multiple sclerosis), neurodegenerative diseases 
(e.g. Alzheimer's disease), ischemia and progression of brain tumors (Zhou et al. 2002). To 
learn more about the role of chemokines in meningiomas and schwannomas, the aims of the 
study were to investigate the expression of three chemokine/receptor pairs 
(CX3CL1/CX3CR1, CXCL12/CXCR4 and CXCL16/CXCR6) on mRNA and protein levels. 
 
4.1  CX3CL1 and CX3CR1 expression in meningiomas 
CX3CL1 is a unique CX3C chemokine acting as an adhesion molecule in its membrane form 
and behaving as a true chemokine in its soluble form. It is one of the most expressed 
chemokines in the brain (Cardona et al. 2006; Harrison et al. 1998; Hatori et al. 2002). 
Neurons and astrocytes are major producers of CX3CL1 and microglial cells express the 
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receptor (Miller et al. 2008; Mizuno et al. 2003); however, CX3CL1 expression has been 
detected also in astrocytes/glial cells (Mizuno et al. 2003; Ludwig et al. 2008), as well as few 
studies documented expression of CX3CR1 in neurons (Meucci et al. 2000). CX3CR1 
expression by tumor cells has been investigated in prostate (Shulby et al. 2004), breast (Andre 
et al. 2006), pancreatic adenocarcinomas (Marchesi et al. 2008) and gliomas (Held-Feindt et 
al. 2011). But limited data are available on the expression of the CX3CL1/CX3CR1 in 
meningiomas.  
In this study, first, the expressions of CX3CL1 and CX3CR1 mRNA were examined by 
real-time RT-PCR in solid tumor materials. Meningiomas originate from arachnoid cap cells 
and have close relationship to the dura. It was very difficult to collect arachnoid cap cells, so 
we chose normal dura tissues, which include also arachnoid cap cells, as controls. On the 
whole, the CX3CL1 mRNA expression level was decreased in meningiomas of all WHO 
grades compared to normal dura. Furthermore, CX3CL1 mRNA expression varied in different 
WHO grades of meningiomas. Compared to normal dura, a statistical significant difference of 
CX3CL1 mRNA expression could be found in meningiomas grade I (P<0.01), II (P<0.05) and 
III (P<0.01). These results were confirmed by IHC, by which lower percentages of CX3CL1 
positive cells were found in meningiomas grade I, II and III in relation to normal dura, though 
statistical significant difference only noted in grade III. Down-regulation of CX3CL1 could be 
found for the first time in meningiomas, especially in WHO grade III. So, lower expression of 
CX3CL1 might be involved in tumorigenesis of human anaplastic meningiomas. Meanwhile, 
as same as the CX3CL1, lower CX3CR1 mRNA expression were found in meningiomas of all 
WHO grades compare to normal dura, and a statistical significant difference could be found in 
meningiomas grade III (P<0.01). The same results were obtained by IHC. Lowest percentage 
of CX3CR1 positive cells was found in meningiomas grade III, and showed a statistical 
difference compared to normal dura (P<0.05). Therefore, the expression of CX3CR1 mRNA 
and protein in poorly differentiated anaplastic meningiomas was obviously lower than that in 
the well differentiated low-grade meningiomas, and, this down-regulated CX3CR1 expression 
indicated the possibility that CX3CR1 was also involved in malignant transformation from 
low-grade meningiomas to high-grade meningiomas. Furthermore, a statistical positive 
correlation between the expression of CX3CL1 and CX3CR1 could be observed in 
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meningiomas grade I, but not in grade II and III. So, CX3CL1 and CX3CR1 were possibly 
co-expressed in benign meningiomas (WHO grade I), and perhaps were unbalanced expressed 
in atypical and anaplastic meningiomas (WHO grade II and III). In conclusion, we could 
demonstrate for the first time, that CX3CL1/CX3CR1 mRNA and protein amounts were 
down-regulated in meningiomas, especially in anaplastic variants, which means lower 
expression of CX3CL1/CX3CR1 axis might plays a pivotal role in the development of human 
anaplastic meningiomas. In addition, unbalanced expression of CX3CL1/CX3CR1 might be 
associated with a malignant tendency of high-grade meningiomas. 
As a matter of fact, regulation of CX3CL1 cleavage has a direct impact on neuronal survival 
both in vitro and in vivo (Cardona et al. 2006). And CX3CR1 mediates protective 
anti-inflammatory effects against neurotoxicity in the brain (Cardona et al. 2006). 
Experimental evidence established that the CX3CL1/CX3CR1 axis plays a major role in the 
neuron/microglia cross-talk, and in neuroprotection under conditions of inflammation/injury 
(Cardona et al. 2006; Harrison et al. 1998; Miller et al. 2008; Mizuno et al. 2003). 
Additionally, animal models of cancer vaccinations based on the overexpression of CX3CL1 
in tumor cells revealed a strong antitumor response (Guo et al. 2003A). The CX3CL1 gene 
was transduced into murine lung carcinoma cells and could induce antitumor immunity 
through chemoattraction and activation of T cells, dendritic cells and natural killer (NK) cells 
(Guo et al. 2003A; Guo et al. 2003B). Murine colon adenocarcinoma cells C26 and melanoma 
B16F10 cells showed that antitumor immune response induced by CX3CL1 gene transfer was 
depended on NK and T cells activation (Xin et al. 2005). However, Lavergne et al (2003) 
reported that in a EL-4 lymphoma model, CX3CL1-mediated antitumor effects occurred only 
via NK cells but not T cells because this antitumor effect was observed only in T cell- and B 
cell-deficient Rag1–/– mice, but was ablated in NK cell-deficient beige mice. So, transfer of 
the CX3CL1 gene into tumor cells could elicit a specific antitumor immunity capable of 
inhibiting tumor growth which leads to increased survival of tumor-bearing hosts (Tang et al. 
2007). In hepatocellular carcinoma patients, high expression of CX3CL1/CX3CR1 correlates 
with better prognosis and fewer recurrences, both local and distant (Matsubara et al. 2007). In 
view of these observations and our results, CX3CL1/CX3CR1 axis would be considered as a 
potentially suitable molecule for immunoprevention or gene therapy in human meningiomas, 
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especially in anaplastic variants. 
 
4.2  CXCL16 and CXCR6 expression in meningiomas 
CXCL16 is one of the two known transmembrane chemokines, which is not only found on 
immune cells, but constitutive expression has also been described on fibroblasts, 
keratinocytes, endothelial cells and cancer cells of different tumourorigin (Hojo et al. 2007;  
Hundhausen et al. 2007; Ludwig et al. 2005; Scholz et al. 2007; Wågsäter et al. 2004; 
Held-Feindt et al. 2008; Ludwig et al. 2008). And its receptor CXCR6 was reported to be 
expressed not only on immune cells, but also on bone marrow plasma cells, smooth muscle 
cells and different tumor cells (Shimaoka et al. 2004; Chandrasekar et al. 2004; Hase et al. 
2006; Matloubian et al. 2000; Hattermann et al. 2008). In a previous study, it was found that 
the ligand CXCL16 was expressed in the normal human brain at capillary endothelial cells 
and abundantly in the human brain in malignant glioma cells and reactive astrocytes in situ 
and in vitro (Ludwig et al. 2005). Furthermore, CXCL16 has been detected in human 
cerebrospinal fluid of patients with inflammatory brain diseases (le Blanc et al. 2006). In 
human endothelial and glioma cells, CXCL16 is induced by IFN-γ and TNF-α and shed to its 
soluble form by the cell-surface proteases ADAM10 and ADAM17 (Abel et al. 2004; Ludwig 
et al. 2005). Nevertheless, nothing is known about the expression and role of 
CXCL16/CXCR6 in human meningiomas. 
Our present study provides that a expression of CXCL16 and CXCR6 were identified in 
normal dura. Compared to normal dura, a down-regulated mRNA expression of CXCL16 was 
found in meningiomas of all different WHO grades. Statistical significant differences could be 
found in meningiomas grade I (P<0.05) and III (P<0.01). Similar results were found by IHC, 
though a statistical significant difference was only noted in grade III (P<0.05). However, we 
could draw the conclusion that a lower expression of CXCL16 mRNA and protein might be 
involved in tumorigenesis of high-grade meningiomas. A statistical significant difference of 
CXCR6 mRNA expression could be found only in meningiomas grade I compared to normal 
dura (P<0.05). With investigation by IHC, CXCR6 protein expression in meningiomas grade I, 
II, III and normal dura were found to be similar, and no statistical significant differences could 
be found between them. Meanwhile, CXCR6 expression was in general low in all investigated 
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samples. So we could not directly draw the conclusion that CXCR6 is involved in the 
development of meningiomas. Nevertheless, a positive correlation between the expression of 
CXCL16 and CXCR6 could be observed in all meningiomas samples (P<0.01). This result 
further support the notion that CXCL16 and CXCR6 are associated with each other in human 
meningiomas. On the whole, these results support the hypothesis that the down-regulated 
expression of CXCL16 might associated with the pathogenesis of human anaplastic 
meningiomas. 
The expression and functional role of CXCL16 and CXCR6 have been investigated in 
different types of tumor. CXCL16 and CXCR6 are always over-expressed in tumor cells, such 
as breast cancer tissues (Ludwig et al. 2005; Matsumura et al. 2008), prostate cancer tissues 
(Hu et al. 2008), colorectal cancer tissues (Hojo et al. 2007), schwannomas (Held-Feindt et al. 
2008) and pancreatic ductal adenocarcinoma (Wente et al. 2008; Gaida et al. 2008). CXCL16 
induces migration and invasion of glial precursor cells via its receptor CXCR6 (Hattermann et 
al. 2008). Furthermore, a tumor promoting role of the CXCL16-CXCR6 axis has been 
reported in schwannomas (Held-Feindt et al. 2008). 82.5% of pancreatic ductal 
adenocarcinoma patients displayed up-regulation of CXCL16 in sera. Additionally, CXCR6 
interacted with trans-membrane CXCL16 to inhibit proliferation in pancreatic carcinoma in 
vitro and in vivo (Wente et al. 2008; Gaida et al. 2008). CXCR6 was also expressed in 
nasopharyngeal carcinoma (NPC) cell lines. For this, soluble CXCL16 attracted migration of 
NPC cells in a dose-dependent manner, and CXCR6 was detected in metastatic tumor tissues, 
but not in primary NPC tumors (Ou et al. 2006). High CXCL16 expression correlated with a 
good prognosis and increased levels of tumor-infiltrating lymphocytes (Hojo et al. 2007). In 
addition, an anti-migratory function of CXCL16 in renal cancer cells was demonstrated with 
migration assay. High CXCL16 expression in patients showed significantly longer overall 
survival times (Gutwein et al. 2009). In contrast, in human rectal cancer, downregulation of 
CXCL16 has been reported, but the correlation between CXCL16 expression and clinical 
outcome of the patients has not been analyzed (Wågsäter et al. 2004). 
Recently, a number of studies have tested the antitumor effects of chemokines. The concept is 
that the expression of specific chemokines at the tumor site may attract T cells, NK cells, and 
dendritic cells bearing relevant chemokine receptors, which possibly leads to the induction of 
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antitumor immunity. Significant tumor suppressive activity was reported for chemokines such 
as CX3CL1 (also called Fractalkine) by transducing their genes into a variety of experimental 
tumors as we mentioned above. It remains to be tested whether CXCL16 has any strong 
antitumor effect in such experimental tumors. 
We here provide the first evidence that the CXCL16 may play only a modest role in the 
pathogenesis of meningiomas. Further experiments have to be done to explore the function of 
CXCL16/CXCR6 axis in human meningiomas. 
 
4.3  CX3CL1 and CXCL12 expression in normal peripheral nerves 
As same as meningiomas, in relation to normal control samples, we decided to investigate the 
expression of chemokines and their receptors on mRNA and protein levels in human 
schwannomas and MPNST as well. Intriguingly, a significant difference of CX3CL1 mRNA 
expression could be found between 2 normal 8
th
 cranial nerves (NCN) and 3 normal spinal 
nerves (NSN) at first. The same results also could be found for CXCL12 mRNA expression 
measured by real-time RT-PCR. So, we demonstrate at first, that a significant expression 
difference of CX3CL1 and CXCL12 between NCN and NSN exist, although the physiological 
role of these chemokines in normal peripheral nerves remains unknown. In view of this, we 
analyze the results in vestibular schwannomas (VS) and spinal schwannomas (SPS) separately, 
compared to NCN and NSN as normal controls, respectively.  
 
4.4  CX3CL1 and CX3CR1 expression in schwannomas 
One chemokine/receptor pair that has been gaining attention in recent years is CX3CL1 and 
CX3CR1. Several reports showed that CX3CL1 is abundantly expressed by the nervous 
system, and also is constitutively expressed by spinal neurons and tethered to the membrane 
of primary afferents, whereas its receptor, CX3CR1, is predominantly expressed by microglia 
(Lindia et al. 2005; Verge et al. 2004; Zhuang et al. 2007). However, little is known about the 
expression and function of CX3CL1 and CX3CR1 in human schwannomas and MPNST. In 
this study, we detected the expression of CX3CL1 and CX3CR1 in VS, SPS and MPNST on 
mRNA and protein level simultaneously for the first time. The VS is generally regarded as a 
benign tumor that originates from the Schwann cells of the vestibular part of the 8
th
 cranial 
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nerve. So, we chose 2 NCN tissues (also included Schwann cells and parts of axons) as 
controls for VS. As a result, lower expression of CX3CL1 mRNA was found in VS compared 
to NCN with a statistical significant difference (P<0.05). Similar results were also found by 
IHC, though the difference was not significant. In contrast, higher expression of CX3CR1 
mRNA and higher percentage of CX3CR1 positive cells were found in VS compared to NCN 
with statistical significant differences (P<0.05).  
Then, we analyzed the CX3CL1/CX3CR1 expression in SPS and MPNST, 3 NSN samples 
served as normal controls. As same as VS, lower expression of CX3CL1 mRNA and lower 
percentages of CX3CL1 positive cells were found in SPS compared to NSN. The differences 
were statistical significant. Meanwhile, higher expression of CX3CR1 mRNA was obtained in 
SPS compared to NSN, although no statistical significant difference could be measured. 
Similar results were also obtained by IHC. To sum up the above results, we may draw the 
conclusion that lower expression of CX3CL1 and higher expression of CX3CR1 might be 
involved in the pathogenesis of human schwannomas (including VS and SPS). In regard to 
MPNST, the malignant form of schwannomas, we found that both the expression of 
CX3CL1/CX3CR1 mRNA and percentages of CX3CL1/CX3CR1 positive cells in MPNST 
were a little bit lower than those in NSN, but no statistical significant difference could be 
found. Moreover, we analyze the possible correlation between the expression levels of 
CX3CL1 and CX3CR1 in VS, SPS and MPNST, but no positive correlation could be 
observed. On the whole, these results support the hypothesis that a down-regulated expression 
of CX3CL1 and a up-regulated expression of CX3CR1 might be associated with the 
pathogenesis of human schwannomas. 
As mentioned above, CX3CL1 acts as an adhesion molecule in its membranous form and 
behaves as a true chemokine in its soluble form. Pancreatic ductal adenocarcinoma cells 
bearing CX3CR1 specifically adhere to CX3CL1-expressing cells of neural origin and 
migrate in response to CX3CL1 produced by neurons and nerve fibers, contributing to 
perineural dissemination in pancreatic cancer (Marchesi et al. 2008). Prostate cancer cells that 
express CX3CR1 adhere to human bone marrow endothelial cells and migrate toward a 
medium conditioned by osteoblasts, which secrete the soluble form of the chemokine 
contributing to the high likelihood of prostate cancer cells metastasizing to the skeleton 
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(Jamieson et al. 2008; Shulby et al. 2004). CX3CL1 also was shown to have tumor 
suppressive activity, following CX3CL1 gene transfer into murine lung carcinoma, colon 
adenocarcinoma, lymphoma and hepatocellular carcinoma cell lines (Guo et al, 2003A; Guo 
et al, 2003B; Xin et al. 2005; Lavergne et al. 2003; Tang et al. 2007). The expression of 
CX3CR1 on NK cells and some T cell subpopulations has been the rationale to exploit 
CX3CL1 in cancer immunotherapy. The dual function of CX3CL1, as chemoattractant for 
leukocytes potentially displaying an antitumor response and as an adhesion molecule for 
tumor cells expressing the receptor may explain clinical discrepancies reported on the role of 
this chemokine/receptor pair in tumors. Further studies are needed to elucidate the role of 
CX3CL1/CX3CR1 in human schwannomas in more detail, also to provide the rationale to 
evaluate them as potential targets for therapeutics. 
 
4.5  CXCL12 and CXCR4 expression in schwannomas 
The last aim of this study was to describe the expression of CXCL12 and CXCR4 in human 
schwannomas on mRNA and protein levels. CXCL12 has been documented to be expressed 
by cells in several different tissues, including endothelial cells in the bone marrow 
(Ponomaryov et al. 2000), distal tubular cells of the kidney (Tögel et al. 2005), and dendritic 
cells in the skin (Pablos et al. 1999). Indeed, in contrast to many chemokines whose 
expression is strongly upregulated during inflammatory responses, both CXCL12 and CXCR4 
are constitutively expressed at high levels in many tissues, including the developing and adult 
nervous systems (Stumm et al. 2002; Stumm et al. 2003). With respect to nervous systems, a 
recent report has shown that meningeal CXCL12 and its receptor CXCR4 are critically 
involved in two distinct aspects of precerebellar neuron migration: (1) confining the migrating 
cells to marginal streams, (2) and promoting the anterior migration of anterior extramural 
stream cells (Zhu et al, 2009). Expression of CXCR4 in the CNS was shown in a variety of 
cell types including astrocytes, microglia, cerebellar granule cells, and neurons (Bajetto et al. 
2002). Recently, CXCR4 expression was also demonstrated on mouse oligodendrocyte 
precursor cells (Dziembowska et al. 2005). In addition, CXCL12 also has been found in 
glioma (Rempel et al. 2000; Zhou et al. 2002; Barbero et al. 2003), medulloblastoma (Rubin 
et al. 2003), lymphoma (Corcione et al. 2000), ovarian (Porcile et al. 2005) and pancreatic 
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cancer (Koshiba et al. 2000). As CXCR4 is expressed on several cancer cells, these 
CXCR4-positive cancer cells may metastasize to organs that secrete/express CXCL12. 
Regarding gliomas, recent data demonstrate that glioma tumor stem-like cells promote tumor 
angiogenesis and vasculogenesis via a CXCL12/CXCR4 pathway (Folkins et al. 2009; 
Hattermann K et al. 2010). In addition, CXCL12/CXCR4 have recently been shown to be 
expressed on primary central nervous system lymphomas, and a role for chemokines in the 
pathogenesis of primary central nervous system lymphomas has been suggested (Brunn et al. 
2007; Smith et al. 2007; Fischer et al. 2009).  
We evaluated CXCL12 and CXCR4 expression in schwannomas (using real-time RT-PCR, 
confirmed by IHC) in a series of surgical schwannomas specimens. As mentioned above, we 
chose 2 NCN tissues as controls for VS and 3 NSN tissues as controls for SPS and MPNST. 
The expression of CXCL12 was identified in all specimens, and its expression levels were 
relatively higher than other chemokines we have measured. Lower expression of CXCL12 
mRNA and lower percentages of CXCL12 positive cells were found in SPS compared to NSN. 
The difference was statistical significant (P<0.01). On the contrary, higher expression of 
CXCL12 mRNA and higher percentages of CXCL12 positive cells were found in VS 
compared to NCN, but no statistical significant difference could be measured. As a matter of 
fact, the expression levels of CXCL12 in VS and SPS were similar. Thus, the significant 
difference of CXCL12 expression between NCN and NSN was the main reason due to this 
opposite results. So, to better understand the physiological role of CXCL12 in normal 
peripheral nerves (including cranial nerve and spinal nerve), further study will be necessary. 
However, as a result of this study, we could draw the conclusion that a lower expression of 
CXCL12 mRNA and protein might be involved in tumorigenesis of human spinal 
schwannomas. As same as CXCL12, CXCR4 mRNA expression in VS was slightly 
up-regulated compared to NCN. In accordance with this, CXCR4 protein expression in VS 
was significant higher than that in NCN and the difference was statistical significant (P<0.05). 
CXCR4 mRNA expression in SPS was a little bit lower than that in NSN, meanwhile, 
CXCR4 protein expression in SPS was a little bit higher than that in NSN. No statistical 
significant differences could be found. Furthermore, in MPNST, the expression levels of 
CXCL12 and CXCR4 were similar to those in NSN, with no statistical significant differences. 
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Moreover, we analyze the possible correlation between the expression levels of CXCL12 and 
CXCR4 in schwannomas (including VS and SPS) and MPNST. A positive correlation 
between the expression of CXCL12 and CXCR4 could be observed in schwannomas (P<0.05), 
but not in MPNST. At least, this result indicated that CXCL12 and CXCR4 were co-expressed 
and associated with each other in human schwannomas at mRNA levels. 
To our knowledge, this is the first report demonstrating the expression of CXCL12 and its 
receptor CXCR4 in schwannomas and MPNST, although CXCL12/CXCR4 was previously 
shown to be involved in the progression of different human tumors, including those 
developing in the brain (Salmaggi et al. 2004; Maderna et al. 2007; Oh et al. 2009; Balkwill. 
2004). CXCL12 and CXCR4 have been detected in adult glioblastoma multiforme, where 
their expression was reported to increase with tumor grade (Rempel et al. 2000). Additionally, 
CXCR4 was found on glioma stem-like cells and was diminished upon differentiation. 
(Hattermann K et al. 2010). In vitro, CXCL12 acts as a growth factor for glioblastoma cell 
lines and normal astrocytes, increasing their proliferation (Bajetto et al. 2001; Barbero et al. 
2003). It has been reported that CXCL12 stimulates chemotaxis, survival, and cell 
proliferation in glioblastoma multiforme, medulloblastoma cell lines and xenografted tumors 
(Bajetto et al. 2006; Rubin et al. 2003). In addition, CXCL12 and CXCR4 were shown to be 
involved in the proliferation of meningeal tumor cells, contributing to the biological features 
of this neoplasm, such as the ability to survive and to grow autonomously (Barbieri et al. 
2006). It is also now clear that CXCR4 signaling regulates the migration and development of 
neural stem cells that form numerous structures in the brain and peripheral nervous systems 
(Belmadani et al. 2005; Li et al. 2008). Interestingly, CXCR4 signaling not only regulates the 
migration and proliferation of neural stem cells but also regulates the growth of axons once 
these cells start to develop into neurons (Lieberam et al. 2005; Pujol et al. 2005). Collectively, 
these studies indicate that CXCL12/CXCR4 may have different regulatory roles in several 
biologic processes. 
Indeed, it has been proposed that CXCL12 or CXCR4 could be a potential target for 
therapeutic intervention. Numerous pharmacological agents exist that can modulate 
CXCL12/CXCR4-induced responses both in vitro and in vivo (Coscia et al. 2004). Inhibitors 
of CXCR4 are already available and currently under investigation in preclinical studies of 
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human cancers (Rubin et al. 2003). Antagonists of CXCR4 receptors such as the drug 
AMD3100 are used clinically to release hematopoietic stem cells into the circulation for 
transplantation purposes (Lemoli et al. 2008). A better understanding of the role of CXCL12 
and CXCR4 in schwannomas will enable a greater manipulation of this important biological 
axis to affect the outcome of the disease.  
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5  Summary 
Meningiomas and schwannomas are common tumors of the nervous system. Most patients 
with meningiomas or schwannomas have a good quality of life. However, reviews of large 
patient groups reveal that this optimistic view is not always satisfying. Accepted alternative 
therapies for patients who have failed surgical intervention are currently limited.  
It is known from large clinical studies that chemokines and their receptors are involved in 
physiological and pathological processes of many human tumors. Limited data are available 
on the role of the chemokine/receptor axis in meningiomas and schwannomas. 
In our study, for the first time, the mRNA and protein expression levels of three 
chemokine/receptor pairs (CX3CL1/CX3CR1, CXCL12/CXCR4 and CXCL16/CXCR6) were 
investigated in human meningiomas and schwannomas by real-time RT-PCR and 
immunohistochemistry. First, lower expressions of CX3CL1, CX3CR1 and CXCL16 were 
found in meningiomas compare to normal dura, especially in anaplastic variants. Lower 
CXCR6 mRNA expression could be found only in meningiomas grade I compared to normal 
dura. Additionally, lower expression of CX3CL1 and higher expression of CX3CR1 were 
found in human schwannomas than that in normal nerves. Lower expression of CXCL12 was 
found in spinal schwannomas compared to normal spinal nerves, with a statistical significant 
difference. Meanwhile, CXCR4 protein expression in vestibular schwannomas was significant 
higher than that in normal cranial nerves. Intriguingly, significant differences of CX3CL1 and 
CXCL12 mRNA expression could be found between 2 normal cranial nerves and 3 normal 
spinal nerves. Finally, correlation analysis showed significant positive correlation between the 
expression of CXCL16 and CXCR6 in all meningiomas. Meanwhile, a positive correlation 
between the expression of CX3CL1 and CX3CR1 could be observed only in meningiomas 
WHO grade I. In regard to schwannomas, a positive correlation between the expression of 
CXCL12 and CXCR4 could be observed. No positive correlation could be observed between 
the expression levels of CX3CL1 and CX3CR1 in all meningiomas and schwannomas. 
Taken together these results showed that chemokines and their receptors are involved in the 
pathogenisis of human meningiomas and schwannomas. In this view, our results provide an 
interesting basis for further investigations that should be performed to characterize the roles 
of chemokines and their receptors in human meningiomas and schwannomas.
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7  Appendix 
7.1  Appendix 1  The clinical data of patients 
Case No. 
Gender 
M / F 
Age at 
diagnosis 
Histology 
Recurrence 
Yes / No 
Detection 
1 F 51 
Meningothelial meningioma 
WHO I 
N Re, I 
2 M 36 
Fibroblastic meningioma 
WHO I 
N Re 
3 F 65 
Meningothelial meningioma 
WHO I 
N Re 
4 F 45 
Meningothelial meningioma 
WHO I 
N Re, I 
5 F 71 
Meningothelial meningioma 
WHO I 
N Re, I 
6 F 54 
Meningothelial meningioma 
WHO I 
N Re 
7 F 79 
Meningothelial meningioma 
WHO I 
N Re 
8 F 65 
Meningothelial meningioma 
WHO I 
N Re 
9 M 59 
Meningothelial meningioma 
WHO I 
N Re 
10 F 73 
Meningothelial meningioma 
WHO I 
N Re 
11 M 56 
Atypical meningioma 
WHO II 
N Re 
12 M 57 
Atypical meningioma 
WHO II 
N Re, I 
13 F 59 
Atypical meningioma 
WHO II 
N Re 
14 F 63 
Atypical meningioma 
WHO II 
N Re 
15 M 81 
Atypical meningioma 
WHO II 
N Re 
16 F 57 
Atypical meningioma 
WHO II 
N Re 
17 F 59 
Atypical meningioma 
WHO II 
N Re, I 
18 F 49 
Atypical meningioma 
WHO II 
N Re 
19 F 69 
Atypical meningioma 
WHO II 
N Re, I 
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20 M 50 
Atypical meningioma 
WHO II 
N Re 
21 F 67 
Anaplastic (malignant) meningioma 
WHO III 
N Re 
22 F 56 
Anaplastic (malignant) meningioma 
WHO III 
N Re 
23 M 46 
Anaplastic (malignant) meningioma 
WHO III 
N Re, I 
24 M 52 
Anaplastic (malignant) meningioma 
WHO III 
N Re 
25 F 60 
Anaplastic (malignant) meningioma 
WHO III 
N Re, I 
26 M 70 
Anaplastic (malignant) meningioma 
WHO III 
N Re, I 
27 M 78 
Anaplastic (malignant) meningioma 
WHO III 
Y Re 
28 M 70 
Malignant peripheral nerve sheath 
tumor 
N Re, I 
29 M 47 
Malignant peripheral nerve sheath 
tumor 
N Re, I 
30 F 58 
Malignant peripheral nerve sheath 
tumor 
N Re 
31 M 69 
Malignant peripheral nerve sheath 
tumor 
N Re 
32 M 71 
Malignant peripheral nerve sheath 
tumor 
N Re 
33 M 57 
Malignant peripheral nerve sheath 
tumor 
N Re 
34 M 33 Vestibular schwannoma N Re, I 
35 F 43 Vestibular schwannoma N Re 
36 M 57 Vestibular schwannoma N Re 
37 M 71 Vestibular schwannoma N Re, I 
38 F 46 Vestibular schwannoma N Re, I 
39 F 54 Vestibular schwannoma N Re 
40 M 73 Spinal schwannoma C5/6 N Re 
41 M 60 Spinal schwannoma T11/12 N Re, I 
42 M 36 Spinal schwannoma T5 N Re, I 
43 F 38 Spinal schwannoma T12/L1 N Re, I 
44 F 69 Spinal schwannoma L3 N Re 
45 F 60 Spinal schwannoma T6/7 N Re 
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7.2  Appendix 2  Reagents, kits and instruments 
RNA Isolation 
Polytron-homogenizer (ULTRA-TURRAX
®
 T25 basic, Germany) 
Centrifuge (Eppendorf 5417R, Germany) 
UV/Visible Spectrophotometer (Ultrospeco 3100 pro, Amersham Biosciences, USA) 
TRIZOL
®
 Reagent (Invitrogen
TM
 Life Technologies, Germany, No.15596-018) 
Chloroform (Carl Roth GmbH, Germany, Lot. 6340.1) 
Isopropyl alcohol (Merck kGaA, Germany, No.1.09634.2500) 
75% ethanol (J. T. Baker, Holland, No.8006) 
 
cDNA Synthesis 
10×Reaction buffer (Promega, USA, No.M198A) 
RNase free DNase (1u/µl, Promega, USA, No.M6101) 
EDTA (Carl Roth GmbH, Germany, Lot. 80431.1) 
Random hexamer primer (100µg/µl, Amersham Biosciences, USA, No.27-2166-01) 
5×Buffer for M-MuLV RT (Fermentas, USA, No.00013612) 
10mM dNTP mix (1.0mM-final concentration, Fermentas, USA, No.R0192) 
RevertAid
TM
 H Minus M-MuLV Reverse Transcriptase (200u/µl, Fermentas, USA, 
No.EP0452) 
 
Real-time RT-PCR 
2×TaqMan Universal PCR Master Mix (Applied Biosystems, USA, No.4326708) 
20×Assays-on-Demand
TM
 Gene Expression Assay Mix 
    GAPDH primer (Applied Biosystems, USA, No.Hs99999905) 
    CX3CL1 primer (Applied Biosystems, USA, No.Hs00171086) 
    CX3CR1 primer (Applied Biosystems, USA, No.Hs00365842) 
    CXCL16 primer (Applied Biosystems, USA, No.Hs00222859) 
    CXCR6 primer (Applied Biosystems, USA, No.Hs00174843)   
    CXCL12 primer (Applied Biosystems, USA, No.Hs00171022) 
    CXCR4 primer (Applied Biosystems, USA, No.Hs00237052) 
MyiQ
TM
 Single Color Real-time PCR Detection System (BIO-RAD, USA)  
 
Immunohistochemistry 
Slicing machine (Jung CM3000, Leica Instruments, Nussloch, Germany) 
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Para-formaldehyde (Merck, Germany, Lot.1.04005.1000) 
Triton X-100 (Merck, Germany, Lot.1.08603.1000) 
Primary antibody 
    CX3CL1 (Mouse mAb, R&D Systems, No.MAB3651) 
    CX3CR1 (Rabbit pAb, Santa Cruz Biotechnology, Inc, No.Sc-30030) 
    CXCL16 (Goat Ab, R&D Systems, No.AF976) 
    CXCR6 (Mouse mAb, R&D Systems, No.MAB699) 
    CXCL12 (Rabbit pAb, Santa Cruz Biotechnology, Inc, No.Sc-28876) 
    CXCR4 (Rabbit pAb, Abcam, No.ab7199) 
Second antibody 
Biotinylated Horse anti Mouse IgG (Vector Laboratories, IHC. Burlingame, CA, 
No.BA-2000) 
Biotinylated Rabbit anti Goat IgG (Vector Laboratories, IHC. Burlingame, CA, 
No.BA-5000) 
Biotin-SP-conjugated AffiniPure F(ab’)2 Fragment Donkey Anti-Rabbit IgG (Jackson 
Immuno Reasearch Laboratories, IHC. No.711-066-152) 
Normal blocking serum 
Donkey (Jackson Immuno Reasearch Laboratories, IHC. No.017-000-121) 
Horse (Jackson Immuno Reasearch Laboratories, IHC. No.008-000-121) 
Rabbit (Jackson Immuno Reasearch Laboratories, IHC. No.011-000-120) 
Normal Goat IgG (R&D Systems, No.AB-108-C) 
Normal Mouse IgG (R&D Systems, No.MAB002) 
Normal Rabbit IgG (R&D Systems, No.AB-105-C) 
ABC Vectastain
®
 Kit (Vector Laboratories INC, Burlingane, USA. No.PK-6100) 
3,3’-diaminobenzidine-tetrahydrochloride (DAB) (Roche Diagnostics GmbH, Germany, 
No.11718096001) 
Mayer’s Hämalaun (Carl Roth GmbH, Germany, No.T865.2) 
RotiClear (Carl Roth GmbH, Germany, No.A538.5) 
RotiMount
®
 (Carl Roth GmbH, Germany, Art.HP68.1) 
Microscope (Axiovert 2000, Carl Zeiss, Germany) 
Camera Zeiss (Axiocam MRc5, Carl Zeiss, Germany) 
Software (AxioVs 40 V4.5.00, Carl Zeiss Imaging Solutions GmbH, Germany) 
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